Long-Term Results of a Randomized Prospective Study Comparing Medical and Surgical Treatment of Barrett's Esophagus

Annals of Surgery

Volumn 237, Issue 3, 2003, Pages 291-298

  Parrilla, Pascual ^a   Martínez De Haro, Luisa F ^a   Ortiz, Angeles ^a   Munitiz, Vicente ^a   Molina, Joaquín ^a   Bermejo, Juan ^a   Canteras, Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; ANTIULCER AGENT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DYSPLASIA; ENDOSCOPY; ESOPHAGUS PH; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HISTOPATHOLOGY; HUMAN; INFLAMMATION; INTERMETHOD COMPARISON; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHOOL CHILD; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TREATMENT PLANNING; ARTICLE; CHILD; COMPARATIVE STUDY; ESOPHAGOSCOPY; ESOPHAGUS; ESOPHAGUS TUMOR; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; STOMACH FUNDOPLICATION; STOMACH PH;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; CHILD; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; ESOPHAGUS; FEMALE; FOLLOW-UP STUDIES; FUNDOPLICATION; GASTRIC ACIDITY DETERMINATION; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES;

EID: 85047691803     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SLA.0000055269.77838.8E     Document Type: Review

References (28)

1. Malesci A, Savarino V, Zenith P, et al. Partial regression of Barrett's esophagus by long term therapy with high-dose omeprazole. Gastrointest Endosc. 1996;44:700-705.
2. Ortiz A, Martínez de Haro LF, Parrilla P, et al. Conservative treatment versus antireflux surgery in Barrett's oesphagus: long-term results of a prospective study. Br J Surg. 1996;83:274-278.
3. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol. 1997;92:582-585.
4. Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med. 1992;326:786-792.
5. Castell DO, Katzka DA. Barrett's esophagus: continuing questions and controversy. Gastrointest Endosc. 1999;49:S5-S8.
6. Klinkenberg-Knol E, Nelis F, Dent, et al. Long-term omeprazole treatment in resistant gastro-esophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661-669.
7. Marshall REK, Anggiansah A, Manifold DK, et al. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. Gut. 1998;43:603-606.
8. Waring JP. Postfundoplication complications. Prevention and management. Gastroenterol Clin North Am. 1999;28:1007-1019.
9. Katz D, Rothstein R, Schned A, et al. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol. 1998;93:536-541.
10. McCallum R, Polepalle S, Davenport K, et al. Role of anti-reflux surgery against dysplasia in Barrett's esophagus. Gastroenterology. 1991; 100(suppl):A121.
11. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. Follow-up of a randomized controlled trial. JAMA. 2001;285:2331-2338.
12. Rydell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical application. Hum Pathol. 1983;14:931-968.
13. Bechi P, Pucciani F, Baldini F, et al. Long-term ambulatory enterogastric reflux monitoring. Validation of a new fiberoptic technique. Dig Dis Sci. 1993;38:1297-1306.
14. Martínez de Haro LF, Ortiz A, Parrilla P. et al. Intestinal metaplasia in patients with columnar-lined esophagus is associated with high levels of duodenogastroesophageal reflux. Ann Surg. 2001;333:34-38.
15. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology. 1996;111:1192-1199.
16. Stein HJ, Kauer WK, Feussner H, et al. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and Nissen fundoplication. J Gastrointest Surg. 1998;2:333-341.
17. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol. 1994;89:989-991.
18. Ortiz A, Martínez de Haro LF, Parrilla P, et al. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors. Br J Surg. 1999;86:1472-1474.
19. Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not warrant normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol. 1998;93:711-716.
20. Csendes A, Braguetto I, Burdiles P, et al. Long-term results of classic antireflux surgery in 152 patients with Barrett's esophagus: clinical, radiologic, endoscopic, manometric and acid reflux test analysis before and late after operation. Surgery. 1998;123:645-657.
21. Chen LQ, Nastos D, Hu ChY, et al. Results of the Collis-Nissen gastroplasty in patients with Barrett's esophagus. Ann Thorac Surg. 1999;68:1014-1021.
22. Hofstetter WL, Peters JH, De Meester TR, et al. Long-term outcome of antireflux surgery in patients with Barrett's esophagus. Ann Surg. 2001;234:532-539.
23. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology. 2000;119:333-338.
24. Yoemans ND, Dent J. Personal review: alarmism or legitimate concerns, about long-term suppression of gastric acid secretion? Aliment Pharmacol Ther. 2000;14:267-271.
25. Hinder RA, Raiser F, Katada N, et al. Results of Nissen fundoplication: a cost analysis. Surg Endosc. 1995;9:1328-1332.
26. Van den Boom G, Go PM, Hameetemar W, et al. Cost effectiveness of medical versus surgical treatment in patients with severe or refractory gastroesophageal reflux disease in The Netherlands. Scand J Gastroenterol. 1996;31:1-9.
27. Viljakka M, Nevalainen J, Isolauri J. Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland. Scand J Gastroenterol. 1997;32:766-772.
28. Nessen SC, Holcomb J, Tomkinson B, et al. Early laparoscopic Nissen fundoplication for recurrent reflux esophagitis: a cost-effective alternative to omeprazole. JSLS. 1999;3:103-106.